CSPC Pharmaceutical Group Ltd. announced that the National Medical Products Administration of the People’s Republic of China has granted approval to conduct clinical trials of the company’s antibody-drug conjugate candidate, SYS-6002.
Nowadays, there are many tools for cancer diagnosis, from imaging techniques to biopsies. In traditional blood tests, liquid biopsy bursts onto the scene as an explosion of possibilities driven by molecular techniques for the detection and sequencing of proteins or genetic material. But specialists are cautious because they know that in liquid biopsies not everything is detected. At the ENA 2022 session “The role of ctDNA in clinical trials,” Marie Morfouace, a translational researcher at the EORTC, presented “ctDNA in clinical trial practice today,” where she described the balance of the possibilities of the liquid biopsy when confronting it with the results in patients offered by the studies published to date.
Newco Vacv Biotherapeutics Ltd. has raised $3 million in a seed round to complete preclinical development of next-generation oncolytic viruses that are engineered to overcome previous shortcomings of this modality.
Parenchyma Biotech Inc. has described aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of cancer and autoimmune disease.
Mablink Bioscience SAS., Université Claude Bernard Lyon 1 and Centre National de la Recherche Scientifique have patented antibody-drug conjugates consisting of antibodies covalently linked to therapeutic drugs through an enzyme-triggered self-immolative linker reported to be useful for the treatment of cancer.
RSS
